Neurocrine Biosciences, Inc. (NASDAQ:NBIX)‘s stock had its “buy” rating reiterated by Robert W. Baird in a note issued to investors on Friday. They currently have a $84.00 price target on the stock. Robert W. Baird’s price target would suggest a potential upside of 14.32% from the company’s previous close.
NBIX has been the topic of a number of other reports. Piper Jaffray Companies restated a “buy” rating and issued a $76.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. Jefferies Group LLC restated a “buy” rating and issued a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. BMO Capital Markets restated an “outperform” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 5th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a report on Thursday, September 7th. Finally, ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $78.88.
Neurocrine Biosciences (NBIX) traded up $0.70 during midday trading on Friday, hitting $73.48. 2,385,825 shares of the stock were exchanged, compared to its average volume of 986,984. The company has a current ratio of 14.38, a quick ratio of 19.36 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 12-month low of $37.35 and a 12-month high of $63.77.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the previous year, the company posted ($0.43) earnings per share. equities research analysts anticipate that Neurocrine Biosciences will post -1.88 earnings per share for the current year.
In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 15,354 shares of the stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $55.00, for a total transaction of $844,470.00. Following the completion of the sale, the insider now directly owns 123,045 shares of the company’s stock, valued at $6,767,475. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Haig P. Bozigian sold 26,250 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the sale, the insider now directly owns 144,601 shares of the company’s stock, valued at $8,676,060. The disclosure for this sale can be found here. Over the last three months, insiders have sold 101,346 shares of company stock valued at $5,879,150. Insiders own 4.80% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in NBIX. Janus Henderson Group PLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $246,888,000. BlackRock Inc. lifted its position in shares of Neurocrine Biosciences by 14,216.0% during the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock valued at $217,884,000 after buying an additional 4,996,784 shares during the last quarter. TimesSquare Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 299.4% during the second quarter. TimesSquare Capital Management LLC now owns 2,315,373 shares of the company’s stock valued at $106,507,000 after buying an additional 1,735,700 shares during the last quarter. HealthCor Management L.P. lifted its position in shares of Neurocrine Biosciences by 108.2% during the second quarter. HealthCor Management L.P. now owns 2,550,178 shares of the company’s stock valued at $117,308,000 after buying an additional 1,325,178 shares during the last quarter. Finally, FMR LLC lifted its position in shares of Neurocrine Biosciences by 9.8% during the second quarter. FMR LLC now owns 13,211,023 shares of the company’s stock valued at $607,707,000 after buying an additional 1,180,874 shares during the last quarter.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
What are top analysts saying about Neurocrine Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neurocrine Biosciences Inc. and related companies.